Frontiers in immunology · 2026
Ozone major blood ozonation in the management of dermatomyositis: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Yunbo, Cui Xinyu, Liu Jiangang, Song Guohua
Аннотация
OBJECTIVE: This case report describes the potential clinical benefit and safety of ozone major blood ozonation (O3-MBO) in the treatment of glucocorticoid (GC)-dependent dermatomyositis.
METHODS: The patient received an initial 15-day daily course of O3-MBO (at a concentration of 80 μg/mL), followed by repeated cycles of 15-day treatment alternating with 15-day rest periods over approximately 15 months. Laboratory parameters and cutaneous lesion status were continuously monitored during the treatment period.
RESULTS: In the case presented, the patient added 15 days of O3-MBO therapy and 15 days of rest as adjunctive therapy without increasing the hormone dosage, which was associated with reductions in serum levels of CK, AST, and ALT, healed the skin ulcers on the shoulders, normalized the skin, reduced the facial edema, and was associated with reduced corticosteroid-related side effects.
CONCLUSION: O3-MBO may serve as a valuable adjunctive treatment for patients with corticosteroid dependence or refractory dermatological symptoms.
METHODS: The patient received an initial 15-day daily course of O3-MBO (at a concentration of 80 μg/mL), followed by repeated cycles of 15-day treatment alternating with 15-day rest periods over approximately 15 months. Laboratory parameters and cutaneous lesion status were continuously monitored during the treatment period.
RESULTS: In the case presented, the patient added 15 days of O3-MBO therapy and 15 days of rest as adjunctive therapy without increasing the hormone dosage, which was associated with reductions in serum levels of CK, AST, and ALT, healed the skin ulcers on the shoulders, normalized the skin, reduced the facial edema, and was associated with reduced corticosteroid-related side effects.
CONCLUSION: O3-MBO may serve as a valuable adjunctive treatment for patients with corticosteroid dependence or refractory dermatological symptoms.